Resources

These short training videos are intended for self-injection clients and health workers learning to administer the contraceptive subcutaneous DMPA (DMPA-SC or Sayana® Press). DMPA-SC's user-friendly design means that any trained person can administer it, including community health workers, pharmacists, and women themselves.The two videos are available in English, French, Portuguese, and Spanish on the DMPA-SC Resource Library. If you are interested in customizing these videos for your family planning program, we can share the voiceover scripts and video files. For more information, please email FPoptions@path.org.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is all-in-one injectable contraceptive that protects against pregnancy for three months. PATH regularly hosts webinars to share the latest evidence and experience from DMPA-SC research, introduction, and scale-up, including self-injection.For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

Thousands of women are now taking charge of their reproductive health through self-injection of the contraceptive subcutaneous DMPA (DMPA-SC, brand name Sayana® Press). In this February 13, 2019 webinar, speakers presented evidence from five countries at different stages of DMPA-SC introduction and scale-up, from earliest (Ghana) to more advanced (Uganda). Speakers also shared insights on applying research findings to program design and delivery. This webinar was hosted by the DMPA-SC Access Collaborative Learning and Action Network.For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

PATH’s Scale-Up project seeked to reduce cervical cancer incidence through improved and expanded screening using human papillomavirus (HPV) testing. Between 2015 and 2020, PATH partnered with countries in Central America to implement HPV testing for cervical cancer screening within public sector clinics. The project demonstrated that a new model of cervical cancer screening anchored on HPV testing is achievable. This resource shares the key findings and public health implications.

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s Self-Injection Best Practices project, which aims to evaluate and identify optimal program models for DMPA-SC self-injection. For more information, sign up for our newsletter, or email FPoptions@path.org.